Court denies Amphastar motion for emergency stay of PI—brief due 11/29/11; new AMGN patent takes Enbrel off list of MNTA’s likely FoB candidates; revised musings on the most likely FoB partners; recent patent applications and overview of IP estate.
... the most likely FoB partners seem a little pharma-centric. Seems like generic companies likely Watson or Sagent would be interested. Also, maybe struggling monoclonal biotechs like IMMU could be in the mix. Even far-fetched scenarios like Sagent acquiring IMMU (< $300M) seem possible.